Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medico RemediesNSE:MEDICO -3.64%81 EV-to-EBIT is 18.63 as of Aug. 19, 2026, which is 44% below its 10-year median of 33.43. GuruFocus rates NSE:MEDICO with a GF Score™ of 81/100 and a GF Value™ of ₹77.43 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 684 Drug Manufacturers companies, Medico Remedies ranks worse than 54.97% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Medico Remedies's Enterprise Value for the quarter that ended in Mar. 2026 was ₹2,873 Mil.
Medico Remedies's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹199 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medico Remedies EV-to-EBIT Related Terms
Medico Remedies EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Medico Remedies's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medico Remedies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medico Remedies EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medico Remedies's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Medico Remedies's EV-to-EBIT falls into.
Medico Remedies's current Enterprise Value is ₹3,701 Mil.
Medico Remedies's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹199 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medico Remedies (NSE:MEDICO) has a EV-to-EBIT of 18.63 as of Aug. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medico Remedies and its competitors. This is 44% below median its historical median of 33.43. Over the past decade, Medico Remedies' EV-to-EBIT has ranged from 16.27 to 229.44. According to the industry distribution chart, Medico Remedies ranks #376 out of 684 companies in the Drug Manufacturers industry, placing it in the top 55%.
Is Medico Remedies' EV-to-EBIT too high?
Medico Remedies' current EV-to-EBIT of 18.63 is 44% below median its 10-year median of 33.43. Over the past 10 years, this metric has ranged from a low of 16.27 to a high of 229.44. The Drug Manufacturers industry median EV-to-EBIT is 15.69. Medico Remedies' value of 18.63 is 18.8% above this industry median. Based on the distribution chart, Medico Remedies ranks #376 out of 684 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Medico Remedies has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medico Remedies' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medico Remedies ranks #376 out of 684 companies for EV-to-EBIT. This places Medico Remedies in the lower half of its industry. The industry median EV-to-EBIT is 15.69. Medico Remedies' value of 18.63 is 18.8% above this benchmark. Historically, Medico Remedies' own EV-to-EBIT has ranged from 16.27 to 229.44 over the past decade. While the company's 10-year median is 33.43 vs. the industry median of 15.69, Medico Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.69, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medico Remedies's current EV-to-EBIT of 18.63 is 18.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medico Remedies and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medico Remedies's current EV-to-EBIT is 18.63, which is 44% below median its own 10-year median of 33.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medico Remedies stock overvalued right now?
Based on GuruFocus' analysis, Medico Remedies (NSE:MEDICO) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹77.43, compared to a current price of ₹42.66 — trading 44.9% below its estimated fair value. The current EV-to-EBIT is 18.63, which is 44% below median its 10-year median of 33.43 and 18.8% above the Drug Manufacturers industry median of 15.69. Medico Remedies' overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Medico Remedies (NSE:MEDICO), the current EV-to-EBIT is 18.63 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medico Remedies (NSE:MEDICO) Overvalued in 2026?
Based on GuruFocus' analysis, Medico Remedies stock appears to be undervalued.
The current stock price of ₹42.66 is trading 44.9% below its estimated GF Value™ of ₹77.43.
GuruFocus considers Medico Remedies to be Significantly Undervalued.
Key valuation signals for NSE:MEDICO:
EV-to-EBIT: 18.63 (44% below median its 10-year median of 33.43)
GF Value™: ₹77.43 vs. price of ₹42.66 (44.9% below fair value)
Industry Position: 18.8% above the Drug Manufacturers median (#376 of 684)
No single metric tells the full story. See the NSE:MEDICO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medico Remedies Ltd is a manufacturer, supplier, and exporter of pharmaceutical drugs. It operates in single segment single segment of manufacturing medicines including Antihy pertensive Antidiabetics Antibictics Diuretics, Antimalarials, NSAIDS Tablets, Antireterovirals, Anti-Ulcer Drugs and Antacids Tablets, so many drugs used for treatment of so many diseases for oral use as well as external preparations like creams & ointments which includes anti infectives ,antifungals ,antibiotics ,steroidal preparations etc. In addition, it also sells other drugs such as antihistaminic, antidiabetics, cardiovascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and cream, and gel for various therapeutic segments.
81GF Score
Get the complete analysis for NSE:MEDICO
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MEDICO has been successfully added to your 
